Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson's Disease.
| Autor: | Bovolenta TM; Programa de Pós-Graduação, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., de Azevedo Silva SM; Movement Disorders Department in Neurology, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil., Arb Saba R; Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil., Borges V; Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil., Ferraz HB; Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil., Felicio AC; Neurology Program, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Parkinson's disease [Parkinsons Dis] 2017; Vol. 2017, pp. 3410946. Date of Electronic Publication: 2017 Mar 05. |
| DOI: | 10.1155/2017/3410946 |
| Abstrakt: | Parkinson's disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than four million people. Typically, it affects individuals above 45, when they are still productive, compromising both aging and quality of life. Therefore, the cost of the disease must be identified, so that the use of resources can be rational and efficient. Additionally, in Brazil, there is a lack of research on the costs of neurodegenerative diseases, such as PD, a gap addressed in this study. This systematic review critically addresses the various methodologies used in original research around the world in the last decade on the subject, showing that costs are hardly comparable. Nonetheless, the economic and social impacts are implicit, and important information for public health agents is provided. Competing Interests: The authors declare that they have no competing interests. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|